Skip to main content
TEYI PHARMACEUTICAL GROUP CO.,LTD logo

TEYI PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002728 ISIN · CNE100001WK6 LEI · 300300ZUIZCFPGQWOZ61 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,596 across all filing types
Latest filing 2022-12-05 Director's Dealing
Country CN China
Listing Shenzhen Stock Exchange 002728

About TEYI PHARMACEUTICAL GROUP CO.,LTD

https://www.tczy.com.cn

TEYI PHARMACEUTICAL GROUP CO.,LTD. specializes in the research, development, manufacturing, and distribution of pharmaceutical products. The company's portfolio primarily consists of Chinese patent medicines and chemical drug preparations. Its flagship product, Zhike Bao Tablets, is widely recognized for treating chronic bronchitis and cough-related ailments. Beyond respiratory health, the group produces a diverse range of medications covering cardiovascular diseases, gastrointestinal disorders, and anti-infective treatments. Teyi Pharmaceutical operates modern production facilities and maintains a robust distribution network to serve healthcare providers and pharmacies. The company emphasizes the integration of traditional medicinal knowledge with modern pharmaceutical technology to enhance product efficacy and safety.

Recent filings

Filing Released Lang Actions
关于公司董事兼高级管理人员减持股份预披露公告
Director's Dealing Classification · 95% confidence The document is a disclosure announcement regarding a planned share reduction by a company director and senior management personnel. It details the shareholder's identity, the number and percentage of shares held, the planned reduction amount, timing, method, and related commitments and risk disclosures. There are no financial statements, earnings data, or report content. The document is a formal notification of insider share transactions, specifically a planned reduction in holdings by a director. This fits the definition of 'Director's Dealing' (DIRS), which covers reports of personal share transactions by company directors and executives (insider trades). The document length is under 5,000 characters and is not an announcement of a report publication or a certification. Therefore, the correct classification is DIRS with high confidence.
2022-12-05 Chinese
可转换公司债券交易异常波动公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the abnormal trading fluctuations of the company's convertible bonds. It provides details about the bond issuance, trading price deviations, and confirms that no undisclosed material information exists. The document is a regulatory disclosure about trading activity and risk warnings, not a financial report or detailed analysis. It is relatively short (1789 characters) and serves as a formal notification to investors and the market. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other specific categories.
2022-11-30 Chinese
股票交易异常波动公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement from the company 特一药业集团股份有限公司 regarding abnormal stock price fluctuations over a specific period (three trading days in late November 2022). It includes statements confirming no undisclosed material information, no changes in business operations, and no need for corrections to previously disclosed information. The document is short (1142 characters) and serves as a regulatory disclosure about stock price movements and compliance with stock exchange rules. It does not contain financial statements, audit information, or detailed management discussion. It is not a report but an announcement related to stock trading activity and regulatory compliance. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-11-30 Chinese
关于第五届董事会第六次会议决议的公告
Board/Management Information Classification · 95% confidence The document is an announcement of resolutions passed at the sixth meeting of the fifth board of directors of 特一药业集团股份有限公司. It includes details about the meeting date, attendance, and voting results on several proposals, such as not redeeming convertible bonds early, changing the auditing firm, and convening an extraordinary general meeting. The document does not contain financial statements or detailed financial data but rather reports on board decisions and meeting outcomes. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors.
2022-11-29 Chinese
关于不提前赎回特一转债的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from a company regarding its decision not to exercise the early redemption rights on its convertible bonds (特一转债). It details the bond issuance, conditions for conditional redemption, the triggering of these conditions, and the company's board resolution not to redeem early. It also includes information about insider trading related to the bonds and future plans. The document is a formal disclosure about financing instruments and capital structure decisions, specifically about convertible bond redemption rights and related board decisions. It is not a full financial report, earnings release, or management discussion, but rather an update on capital/financing activities. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length is 3661 characters, which is sufficient for a detailed announcement but not a full report. No indication that this is a report publication announcement or regulatory filing fallback. Hence, classification is CAP with high confidence.
2022-11-29 Chinese
关于第五届监事会第六次会议决议的公告
Board/Management Information Classification · 95% confidence The document is an announcement of the resolution passed at the sixth meeting of the fifth Supervisory Board of the company. It discusses the approval of a proposal to change the accounting firm for the 2022 financial audit. The document includes meeting details, voting results, and states that the proposal will be submitted to the shareholders' meeting for approval. It does not contain any financial statements or detailed audit results itself, nor is it a full audit report or annual report. It is a formal announcement related to board/management decisions, specifically about the appointment of auditors, which falls under Board/Management Information (MANG). The document length is short and it is not a report publication announcement or certification. Therefore, the best classification is MANG.
2022-11-29 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.